Clinical Trials Browser

Phase 1/2 × Intestinal Neoplasms × Injections × Clear all

NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms